| EMA number | EMEA/H/C/002291 |
| ATC code | N04BC05 |
| Authorisation | 29 September 2011 |
| Withdrawn | 13 April 2022 |
| Revision | 10 |
Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).